drugset
drugset / Trial / NCT05298787

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

NCT05298787 ↗

Phase 1 Completed 56 enrolled ReAlta Life Sciences, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety, tolerability, PK, and PD of single- and multiple-ascending doses of RLS-0071 in healthy adult subjects.

Timeline

Start
2021-01-13
Primary completion
2021-08-16
Completion
2021-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject RLS-0071 Peptide 2 mg/kg Intravenous
Subject RLS-0071 Peptide 10 mg/kg Intravenous
Subject RLS-0071 Peptide 40 mg/kg Intravenous
Subject RLS-0071 Peptide 120 mg/kg Intravenous

Indications

No indication recorded.